206 related articles for article (PubMed ID: 27910003)
1. Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia.
Ismail MM; Abdulateef NAB
Int J Hematol; 2017 Apr; 105(4):453-464. PubMed ID: 27910003
[TBL] [Abstract][Full Text] [Related]
2. A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
Norkin M; Chang M; An Q; Leather H; Katragadda L; Li Y; Moreb JS; May WS; Brown RA; Hsu JW; Hiemenz JW; Wingard JR; Cogle CR
Leuk Res; 2016 Jul; 46():69-73. PubMed ID: 27132034
[TBL] [Abstract][Full Text] [Related]
3. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Chretien AS; Fauriat C; Orlanducci F; Rey J; Borg GB; Gautherot E; Granjeaud S; Demerle C; Hamel JF; Cerwenka A; von Strandmann EP; Ifrah N; Lacombe C; Cornillet-Lefebvre P; Delaunay J; Toubert A; Arnoulet C; Vey N; Olive D
Oncotarget; 2017 Jul; 8(30):49548-49563. PubMed ID: 28548938
[TBL] [Abstract][Full Text] [Related]
4. Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Qian Z; Wen XM; Zhou JD; Li XX; Xu ZJ; Ma JC; Zhang ZH; Lin J; Qian J
Pathol Res Pract; 2018 Jun; 214(6):896-901. PubMed ID: 29627222
[TBL] [Abstract][Full Text] [Related]
5. Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia.
Chen YK; Hou HA; Tang JL; Jhuang JY; Lai YJ; Lee MC; Kuo YY; Chou WC; Liu CY; Lin CW; Chuang SS; Chen CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
PLoS One; 2015; 10(3):e0119831. PubMed ID: 25794001
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
7. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
8. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
Hussein K; Jahagirdar B; Gupta P; Burns L; Larsen K; Weisdorf D
Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
[TBL] [Abstract][Full Text] [Related]
9. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
[TBL] [Abstract][Full Text] [Related]
10. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia.
Wu Z; Chen R; Wu L; Zou L; Ding F; Wang M; Liu X
Clin Transl Oncol; 2017 Dec; 19(12):1462-1468. PubMed ID: 28589431
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia.
Alcasid M; Ma L; Gotlib JR; Arber DA; Ohgami RS
Int J Lab Hematol; 2017 Apr; 39(2):129-136. PubMed ID: 28133918
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis: A biomarker of high-risk phenotype in pediatric acute myeloid leukemia?
Tyagi A; Pramanik R; Bakhshi R; Vishnubhatla S; Bakhshi S
Int J Lab Hematol; 2019 Feb; 41(1):141-147. PubMed ID: 30383325
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
16. Analysis of hematogones in bone marrow from acute myeloid leukaemia cases posttherapy.
Zheng J; Du W; Yao J; You Y; Li W; He Y; Li X; Liu W; Wu Y; Hu Y; Jin R; Zou P; Huang S; Hu Y; Zhang M
Eur J Clin Invest; 2013 Nov; 43(11):1140-6. PubMed ID: 23992300
[TBL] [Abstract][Full Text] [Related]
17. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival.
Tzankov A; Strasser U; Dirnhofer S; Menter T; Arber C; Jotterand M; Rovo A; Tichelli A; Stauder R; Günthert U
Ann Hematol; 2011 Aug; 90(8):901-9. PubMed ID: 21274712
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
19. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies.
De Angulo G; Yuen C; Palla SL; Anderson PM; Zweidler-McKay PA
Cancer; 2008 Jan; 112(2):407-15. PubMed ID: 18058809
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission.
Chen BB; Hsu CY; Yu CW; Hou HA; Liu CY; Wei SY; Chou WC; Tien HF; Shih TT
Radiology; 2011 Mar; 258(3):821-31. PubMed ID: 21212370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
